IPP Bureau

Star Health Insurance partners with Medi Assist to transform claims through AI and Digital Innovation
Star Health Insurance partners with Medi Assist to transform claims through AI and Digital Innovation

By IPP Bureau - June 27, 2025

Star Health Insurance is modernising its claims ecosystem to be future-ready

SMS Pharmaceuticals completes USFDA inspection at Central Laboratory Analytical Services
SMS Pharmaceuticals completes USFDA inspection at Central Laboratory Analytical Services

By IPP Bureau - June 27, 2025

The inspection concluded with zero Form 483 observations

Lupin launches Prucalopride tablets in US
Lupin launches Prucalopride tablets in US

By IPP Bureau - June 27, 2025

Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA

Philogen withdraws marketing authorization application for Nidlegy in EU
Philogen withdraws marketing authorization application for Nidlegy in EU

By IPP Bureau - June 26, 2025

The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls

Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series

By IPP Bureau - June 26, 2025

The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability

Ashland expands viatel bioresorbable polymers offering for medical devices
Ashland expands viatel bioresorbable polymers offering for medical devices

By IPP Bureau - June 26, 2025

Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants

Teijin Pharma receives approval for additional indication for XEOMIN in Japan
Teijin Pharma receives approval for additional indication for XEOMIN in Japan

By IPP Bureau - June 26, 2025

Covestro launches localized production of medical-grade TPU in Asia Pacific
Covestro launches localized production of medical-grade TPU in Asia Pacific

By IPP Bureau - June 25, 2025

Changhua site meets international regulatory standards for global medical applications

Glenmark Pharmaceuticals launches TEVIMBRA in India
Glenmark Pharmaceuticals launches TEVIMBRA in India

By IPP Bureau - June 25, 2025

TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)

Briefs: J B Chemicals and Pharmaceuticals, Concord Biotech and Gland Pharma
Briefs: J B Chemicals and Pharmaceuticals, Concord Biotech and Gland Pharma

By IPP Bureau - June 25, 2025

J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA

Bachem expands multi-site production capacities to meet rising demand
Bachem expands multi-site production capacities to meet rising demand

By IPP Bureau - June 25, 2025

The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland

Lupin receives USFDA approval for Prucalopride Tablets
Lupin receives USFDA approval for Prucalopride Tablets

By IPP Bureau - June 25, 2025

Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults

Archish Fertility & IVF partners with Amaha Health for patient support and mental wellbeing
Archish Fertility & IVF partners with Amaha Health for patient support and mental wellbeing

By IPP Bureau - June 24, 2025

This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

By IPP Bureau - June 24, 2025

First and only TROP2-directed therapy approved in the US for the treatment of lung cancer

Biocon Biologics collaborates with National Cancer Society Malaysia
Biocon Biologics collaborates with National Cancer Society Malaysia

By IPP Bureau - June 24, 2025

The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints

Latest Stories

Interviews

Packaging